FIGURE 3.

TNB‐383B pro‐CTL function activity ex vivo. A, Interaction of treatment analysis to determine the impact of treatment (TNB‐383B vs negative control) and dose (0.001 to 1 μg) on CTL distribution and degranulation (CD107a expression). Tukey's sequential trend test was performed for each experimental treatment group, and each variable tested, utilizing ANOVA models and contrast statements to detect a linear trend in experiments involving increasing doses. B, Dose‐dependent CTL degranulation (CD107a MFI normalized to untreated) induced by TNB‐383B using E_max parametric model to estimate dose response curves, interpolating between tested doses. C, Median E:T ratio (4.8) was used as a cutoff value to test the effect PC and CTL relative distributions on TNB‐383B‐induced PC lysis, viability (7‐AAD⁻) and death by apoptosis (Annexin‐V⁺) by factorial ANOVA